Skip to main content
Novo NordiskIn development

New weight-loss drugs: what 6 drugmakers are testing

Source: Autobound Signal API · 93 signals tracked for Novo Nordisk · updated

Get Novo Nordisk's live signals in Claude or ChatGPT, or by API

AskWhat changed at Novo Nordisk this week? Use Autobound signals for novonordisk.com.

What happened

Novo Nordisk is developing CagriSema and amycretin as new weight-loss drugs.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Wegovy and Zepbound became blockbuster treatments, and drugmakers are now placing bets on what comes after them. The new weight-loss drugs moving through company pipelines range from a compound known only by its code name to a candidate that already carries a brand name. Those bets come from Novo Nordisk, Eli Lilly $LLY and other drugmakers. Reuters surveyed the field in a roundup of weight-loss treatments in development. That roundup covers far more drugmakers than this article does. The six companies here are a selection drawn from it. They are not a ranking, and their order says nothing about which drug is likely to succeed. Novo Nordisk is developing CagriSema and amycretin. Eli Lilly 's lineup includes Foundayo, retatrutide and EloraTZP. Pfizer $PFE is working on a candidate identified so far only by its code name, PF-3944. Roche has enicepatide, a dual-acting drug it gained through its $2.7 billion purchase of U.S. biotech Carmot Therapeutics in 2023. Amgen $AMGN is testing MariTide in six late-stage trials covering obesity and related conditions. Viking Therapeutics is developing VK2735, which comes in two forms that share one name. The numbers in the slides that follow need careful reading. Each trial result here was reported by the company behind the drug. The trials also differ in who took part, how long they lasted and what stage of testing they reached. A...

Keep reading with a free account

The rest of this article, and every signal for Novo Nordisk, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
CagriSema and amycretin

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
90%
Detected
Oct 28, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Novo Nordisk and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Novo Nordisk this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/4ca2c2c6-fa57-5ee6-ba26-76702bc9d8b5 returns this record as JSON. POST /v1/companies/enrich returns every signal for novonordisk.com.

{
  "signal_id": "4ca2c2c6-fa57-5ee6-ba26-76702bc9d8b5",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-28T15:10:23+00:00",
  "company": {
    "name": "Novo Nordisk",
    "domain": "novonordisk.com"
  },
  "data": {
    "url": "https://qz.com/new-weight-loss-drugs-6-drugmakers",
    "title": "New weight-loss drugs: what 6 drugmakers are testing - qz.com",
    "excerpt": "Wegovy and Zepbound became blockbuster treatments, and drugmakers are now placing bets on what comes after them. The new weight-loss drugs moving through company pipelines range from a compound known only by its code name to a candidate that already carries a brand name. Those bets come from Novo Nordisk, Eli Lilly $LLY and other drugmakers. Reuters surveyed the field in a roundup of weight-loss treatments in development. That roundup covers far more drugmakers than this article does. The six companies here are a selection drawn from it. They are not a ranking, and their order says nothing about which drug is likely to succeed. Novo Nordisk is developing CagriSema and amycretin. Eli Lilly 's lineup includes Foundayo, retatrutide and EloraTZP. Pfizer $PFE is working on a candidate identified so far only by its code name, PF-3944. Roche has enicepatide, a dual-acting drug it gained through its $2.7 billion purchase of U.S. biotech Carmot Therapeutics in 2023. Amgen $AMGN is testing MariTide in six late-stage trials covering obesity and related conditions. Viking Therapeutics is developing VK2735, which comes in two forms that share one name. The numbers in the slides that follow need careful reading. Each trial result here was reported by the company behind the drug. The trials also differ in who took part, how long they lasted and what stage of testing they reached. A...",
    "product": "CagriSema and amycretin",
    "summary": "Novo Nordisk is developing CagriSema and amycretin as new weight-loss drugs.",
    "planning": true,
    "image_url": "https://qz.com/cdn-cgi/image/width=1200,quality=85,format=auto/https://assets.qz.com/media/quartz-run-1250-hero-0-9699-300x201.jpg",
    "confidence": 0.9,
    "product_data": {
      "name": "CagriSema and amycretin",
      "full_text": "CagriSema and amycretin",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-28T15:10:23Z",
    "article_sentence": "Novo Nordisk is developing CagriSema and amycretin."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.